EUVIMEDEUVIMED entdecken
Crossref

Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts

Dawei Ni, Beibei Guo, Zhangyan Zhong, Yu Chen, Guang Yang, Jiangtao Yang, Zhiyuan Zhong, Fenghua Meng

Acta Biomaterialia · 2023

DOI: 10.1016/j.actbio.2023.08.043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2023. Verfasst von Dawei Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and …. Hauptthemen laut MEDLINE: Lung Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Actively targeted nanomedicines though conceptually attractive for tumor therapy are extremely hard to realize due to problems of premature drug leakage, excessive liver accretion, inadequate tumor uptake, and/or retarded drug release inside tumor cells. Here, we systemically studied the influence of disulfide crosslinking on the in vitro and in vivo performance of integrin-targeting micellar docetaxel (t-MDTX). Of note, t-M5DTX with a high disulfide content was clearly advantageous in terms of stability, intracellular drug release, anti-tumor activity toward αVβ3-overexpressing A549 cells, blood circulation and therapeutic efficacy in orthotopic A549-luc lung tumor-bearing mice. t-MDTX induced extraordinary tumor targetability with tumor-to-normal tissue ratios of 1.7-8.3. Further studies indicated that t-M5DTX could effectively eradicate αVβ3-overexpressing lung and prostate cancer patient-derived xenografts (PDX), in which ca. 80% mice became tumor-free. This integrin-targeting disulfide-crosslinked micellar docetaxel emerges as a promising actively targeted nanoformulation for tumor therapy. STATEMENT OF SIGNIFICANCE: Nanomedicines have a great potential in treating advanced tumor patients; however, their tumor-targeting ability and therapeutic efficacy remain unsatisfactory. In addition to PEGylation and ligand selection, particle size, stability and drug release behavior are also critical to their performance in vivo. In this paper, we find that small and cRGD-guided disulfide-crosslinked micellar docetaxel (t-MDTX) induces superior tumor uptake and retention but without increasing liver burden, leading to extraordinary selectivity and inhibition of αvβ3 overexpressing lung tumors. t-MDTX is further shown to effectively treat αvβ3-positive patient-derived tumor models, lending it a high potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProstatic NeoplasmsMaleHumansAnimalsMiceDocetaxelMicellesIntegrinsDisulfidesHeterograftsPeptides, CyclicLungCell Line, Tumor

Stichwörter der Autor:innen

DisulfideMicellesNanomedicinesSolid tumorTargeted chemotherapy

Substanzen

DocetaxelMicellesIntegrinsDisulfidesPeptides, Cyclic

Autor:innen und Institutionen

  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China.
  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China; College of Ph…
  • GenePharma, Suzhou 215123, PR China.
  • Department of Oncology, Suzhou BenQ Medical Center, the Affiliated BenQ Hospital of Nanjing Medical University, Suzhou 215009, PR China.
  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China. Electronic ad…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ni, D., Guo, B., Zhong, Z., Chen, Y., Yang, G., Yang, J., Zhong, Z., & Meng, F. (2023). Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2023.08.043

Vancouver

Ni D, Guo B, Zhong Z, Chen Y, Yang G, Yang J, et al. Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts. Acta Biomaterialia. 2023. doi:10.1016/j.actbio.2023.08.043

BibTeX
@article{Ni2023,
  author = {Ni, Dawei and Guo, Beibei and Zhong, Zhangyan and Chen, Yu and Yang, Guang and Yang, Jiangtao and Zhong, Zhiyuan and Meng, Fenghua},
  title = {Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts},
  journal = {Acta Biomaterialia},
  year = {2023},
  doi = {10.1016/j.actbio.2023.08.043}
}
Kostenlos starten →